{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:42:25Z","timestamp":1788867745616,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jdiacomp.2024.108932","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T08:05:59Z","timestamp":1733731559000},"page":"108932","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["The effect of semaglutide combined with metformin on liver inflammation and pancreatic beta-cell function in patients with type 2 diabetes and non-alcoholic fatty liver disease"],"prefix":"10.1016","volume":"39","author":[{"given":"Rong","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxia","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lufei","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2024.108932_bb0005","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3803\/EnM.2022.605","article-title":"DPP-4 inhibitor in type 2 diabetes mellitus patient with non-alcoholic fatty liver disease: achieving two goals at once?","volume":"37","author":"Bae","year":"2022","journal-title":"Endocrinol Metab (Seoul, Korea)"},{"key":"10.1016\/j.jdiacomp.2024.108932_bb0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11892-021-01383-7","article-title":"The relationship between type 2 diabetes, NAFLD, and cardiovascular risk","volume":"21","author":"Caussy","year":"2021","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.jdiacomp.2024.108932_bb0015","doi-asserted-by":"crossref","first-page":"686","DOI":"10.47102\/annals-acadmedsg.2022284","article-title":"Non-alcoholic fatty liver disease screening in type 2 diabetes mellitus: a cost-effectiveness and price threshold analysis","volume":"51","author":"Choo","year":"2022","journal-title":"Ann Acad Med Singapore"},{"key":"10.1016\/j.jdiacomp.2024.108932_bb0020","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3803\/EnM.2022.1635","article-title":"Performance of simple fibrosis score in non-alcoholic fatty liver disease with and without type 2 diabetes","volume":"38","author":"Chung","year":"2023","journal-title":"Endocrinol Metab (Seoul, Korea)"},{"key":"10.1016\/j.jdiacomp.2024.108932_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.610893","article-title":"The effects of vitamin D supplementation on metabolic and oxidative stress markers in patients with type 2 diabetes: a 6-month follow up randomized controlled study","volume":"12","author":"Cojic","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.jdiacomp.2024.108932_bb0030","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41574-023-00833-4","article-title":"Metformin: update on mechanisms of action and repurposing potential","volume":"19","author":"Foretz","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jdiacomp.2024.108932_bb0035","article-title":"Metformin alleviates hepatic steatosis and insulin resistance in a mouse model of high-fat diet-induced nonalcoholic fatty liver disease by promoting transcription factor EB-dependent autophagy","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jdiacomp.2024.108932_bb0040","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejim.2022.03.025","article-title":"Non-alcoholic fatty liver disease: identical etiologic factors in patients with type 1 and type 2 diabetes","volume":"100","author":"de Vries","year":"2022","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jdiacomp.2024.108932_bb0045","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13543","article-title":"Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: a network meta-analysis of randomized clinical trials","volume":"24","author":"Alkhezi","year":"2023","journal-title":"Obes Rev"},{"key":"10.1016\/j.jdiacomp.2024.108932_bb0050","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.eprac.2023.11.007","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists on body weight and cardiometabolic parameters in individuals with obesity and without diabetes: a systematic review and meta-analysis","volume":"30","author":"Ansari","year":"2024","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jdiacomp.2024.108932_bb0055","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s12325-021-01710-0","article-title":"Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists","volume":"38","author":"Ard","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.jdiacomp.2024.108932_bb0060","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.2147\/JIR.S391859","article-title":"Effects of semaglutide on cardiac protein expression and cardiac function of obese mice","volume":"15","author":"Pan","year":"2022","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.jdiacomp.2024.108932_bb0065","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/eat.24109","article-title":"Use of glucagon-like peptide-1 receptor agonists in eating disorder populations","volume":"57","author":"Bartel","year":"2024","journal-title":"Int J Eat Disord"},{"key":"10.1016\/j.jdiacomp.2024.108932_bb0070","article-title":"Mechanisms of non-alcoholic fatty liver disease and beneficial effects of semaglutide: a review","volume":"16","author":"Alfawaz","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.jdiacomp.2024.108932_bb0075","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jgh3.12780","article-title":"Efficacy and safety of oral semaglutide in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus: a pilot study","volume":"6","author":"Arai","year":"2022","journal-title":"JGH Open"},{"key":"10.1016\/j.jdiacomp.2024.108932_bb0080","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.62347\/RYLN5360","article-title":"Efficacy and safety of semaglutide combined with metformin in treating T2DM with overweight or obesity: a systematic review and meta-analysis","volume":"16","author":"Li","year":"2024","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.jdiacomp.2024.108932_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24119677","article-title":"Type 2 diabetes mellitus, non-alcoholic fatty liver disease, and metabolic repercussions: the vicious cycle and its interplay with inflammation","volume":"24","author":"Frankowski","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jdiacomp.2024.108932_bb0090","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1055\/a-1089-7991","article-title":"Association of the triglyceride to high-density lipoprotein ratio and the visceral adiposity index with metabolic syndrome in diabetic susceptible population","volume":"52","author":"Huang","year":"2020","journal-title":"Horm Metab Res = Hormon- und Stoffwechselforschung = Hormones et metabolisme"},{"key":"10.1016\/j.jdiacomp.2024.108932_bb0095","first-page":"418","article-title":"Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (Version 2024)","volume":"32","year":"2024","journal-title":"Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chin J Hepatol"},{"key":"10.1016\/j.jdiacomp.2024.108932_bb0100","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/17512433.2024.2306223","article-title":"Metformin adverse event profile: a pharmacovigilance study based on the FDA Adverse Event Reporting System (FAERS) from 2004 to 2022","volume":"17","author":"Du","year":"2024","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jdiacomp.2024.108932_bb0105","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1001\/jama.2023.22949","article-title":"Metformin plus insulin for preexisting diabetes or gestational diabetes in early pregnancy: the MOMPOD randomized clinical trial","volume":"330","author":"Boggess","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jdiacomp.2024.108932_bb0110","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.3748\/wjg.v29.i37.5327","article-title":"Efficacy and safety of semaglutide in non-alcoholic fatty liver disease","volume":"29","author":"Zhu","year":"2023","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jdiacomp.2024.108932_bb0115","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/biolre\/ioad032","article-title":"Glucagon-like peptide-1 receptor agonists decrease hyperinsulinemia and hyperandrogenemia in dehydroepiandrosterone-induced polycystic ovary syndrome mice and are associated with mitigating inflammation and inducing browning of white adipose tissue\u2020","volume":"108","author":"Zhang","year":"2023","journal-title":"Biol Reprod"},{"key":"10.1016\/j.jdiacomp.2024.108932_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25052961","article-title":"Semaglutide improves liver steatosis and de novo lipogenesis markers in obese and type-2-diabetic mice with metabolic-dysfunction-associated steatotic liver disease","volume":"25","author":"Soto-Catal\u00e1n","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jdiacomp.2024.108932_bb0125","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/dom.15383","volume":"26","author":"Wu","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2024.108932_bb0130","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2024.108932_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2023.108610","article-title":"Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"37","author":"Shi","year":"2023","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jdiacomp.2024.108932_bb0140","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/apt.17598","article-title":"Improved health-related quality of life with semaglutide in people with non-alcoholic steatohepatitis: a randomised trial","volume":"58","author":"Romero-G\u00f3mez","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jdiacomp.2024.108932_bb0145","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/dom.15312","article-title":"Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus","volume":"26","author":"Tsukamoto","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2024.108932_bb0150","article-title":"Fecal microbiota transplantation reverses insulin resistance in type 2 diabetes: a randomized, controlled, prospective study","volume":"12","author":"Wu","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.jdiacomp.2024.108932_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.149882","article-title":"Semaglutide alters gut microbiota and improves NAFLD in db\/db mice","volume":"710","author":"Mao","year":"2024","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jdiacomp.2024.108932_bb0160","article-title":"Chronic disease management, self-efficacy and quality of life","volume":"29","author":"Chan","year":"2021","journal-title":"J Nurs Res"},{"key":"10.1016\/j.jdiacomp.2024.108932_bb0165","article-title":"Anesthesia considerations for a patient on semaglutide and delayed gastric emptying","volume":"15","author":"Fujino","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.jdiacomp.2024.108932_bb0170","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","article-title":"Association of semaglutide with risk of suicidal ideation in a real-world cohort","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872724002587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872724002587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T11:53:25Z","timestamp":1739015605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872724002587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1056872724002587"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2024.108932","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of semaglutide combined with metformin on liver inflammation and pancreatic beta-cell function in patients with type 2 diabetes and non-alcoholic fatty liver disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2024.108932","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024","name":"copyright","label":"Copyright"}],"article-number":"108932"}}